First LES Survey of Biopharma Licensing Terms Finds More Value in Downstream Tech

The report, entitled the LES Biopharmaceutical Royalty Rates and Deal Terms Survey, was the first of its kind. The Licensing Executives Society conducted it in an attempt to provide data and insights about licensing deals in the biotechnology and pharmaceutical sectors that have in the past been difficult to obtain.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.